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Summary
Glioblastoma (GBM) is a malignant brain tumor with few therapeutic options. The disease presents with
a complex spectrum of genomic aberrations, but the pharmacological consequences of these aberrations are
partly unknown. Here, we report an integrated pharmacogenomic analysis of 100 patient-derived GBM cell
cultures from the Human Glioma Cell Culture (HGCC) cohort. Exploring 1544 drugs, we find that GBM has
two main pharmacological subgroups, marked by differential response to proteasome inhibitors and mutually
exclusive aberrations in TP53 and CDKN2A/B. We confirm this trend in cell and in xenotransplantation models,
and identify both Bcl-2 family inhibitors and p53 activators as potentiators of proteasome inhibitors for GBM
treatment. We can further predict the responses of individual cell lines to several drug classes, presenting
opportunities for drug repurposing and design of stratified trials. Our functionally profiled biobank provides a
valuable resource for the discovery of new treatments for GBM.
Keywords: Biobank, Combination Therapy, Data Integration, Glioblastoma, Multi-omics, p53 reactivators,
Patient-derived cells, Primary cells, Proteasome
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Introduction
The pharmacological treatment of glioblastoma (GBM) remains one of the hardest challenges in cancer preci-
sion therapy. An increasing volume of genetic data has clarified that GBM tumors present with multiple and
diverse genetic aberrations in receptor tyrosine kinase (RTK), p53 and other pathways (Brennan et al., 2013;
Taylor et al., 2019). Despite these advances, current therapy is based on a combination of surgery, radiation,
and temozolomide, resulting in a median survival of 14.6 months, of which a mere 2.5 months are attributed to
the chemotherapy (Stupp et al., 2005). Targeted intervention against key recurrent oncogenes in the RTK path-
ways, EGFR and PDGFRA, does not improve overall survival in unselected cohorts (Lee et al., 2015; Reardon
et al., 2015; Brown et al., 2008). The impact of tumor diversity on GBM pharmacology thus remains to be
elucidated.
To address this challenge, collections of patient-derived GBM cell cultures provide us with a powerful tool to
explore and define possible pharmacological responses in GBM (Pollard et al., 2009; Xie et al., 2015). The
analysis of drug response across a panel of GBM cell cultures gives a relatively unbiased estimate of how
drug responses vary, and their correlation (if any) with patient-specific factors, such as age, sex (?), frequent
mutations, or transcriptional subtype (Verhaak et al., 2010; Wang et al., 2017). In recent work, Lee et al.
demonstrated that patient-derived GBM cells treated with drugs approved for oncology indications - predomi-
nantly kinase inhibitors - respond in a manner that can be predicted based on their somatic mutations (Lee et al.,
2018). Traditional GBM cell lines, such as U87MG (Allen et al., 2016), have also been included in compara-
tive pharmaco-genomic screens of tumor cell lines from diverse tissue origins (Kutalik et al., 2008; Barretina
et al., 2012; Garnett et al., 2012; ?; Basu et al., 2013; Seashore-Ludlow et al., 2015; Iorio et al., 2016). Despite
these advances, the number of drug classes analyzed in well-characterized patient-derived GBM cell cultures
remains limited, and there is scarce data to connect common drug classes to cellular pathways in GBM.
Here, we report a systematic effort to define the known and unknown pharmacological subclasses of GBM.
Our strategy connects pharmacological and genomic profiling of 100 patient-derived GBM cell cultures, with
computational modeling, to identify (i) drugs and mechanisms-of-action with activity against primary GBM
cells (ii) the key pathways associated to drug response; and (iii) combinatorial interventions based on drug-
pathway associations (Figure 1A). Previously, our laboratory has genetically characterized the Human Glioma
Cell Culture (HGCC) resource of 48 public primary GBM lines, which has a broad distribution (Xie et al.,
2015). The extended effort presented here aims to meet an unmet need for a large set of highly characterized
cell models, with clinical annotations, comprehensive molecular information, as well as pharmacological and
functional data.
From an unbiased survey of 1,544 compounds that comprise 116 mechanisms-of-action (MOA), we identify
a set of 248 drugs with GBM activity after 72 hours of exposure. We use the variation in dose-dependent
response to these drugs to define the main pharmacological classes of GBM and construct models that connect
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each individual drug (and drug class) to pathways and individual markers. The resulting map substantially
extends the set of drug categories that can be predicted with accuracy in GBM, defines 51 associations between
drug classes and hallmark pathways, and nominate biomarkers for drugs with both oncology and non-oncology
indications. We find that GBM cultures exist in two main functional classes, not captured by current subtype
systems. The classes are characterized by mutually exclusive p53 mutation and deletion of the CDKN2A/B
locus, and differential sensitivity to proteasome inhibitors, a class of drugs that block the cellular catalysis of
ubiquitinated proteins, leading to a surge of reactive oxygen species (ROS) and apoptotic cell death (Richardson
et al., 2005; Ling et al., 2003; Lipchick et al., 2016). Exploiting additional compounds targeting pathways
linked to p53 and proteins encoded by the CDKN2A/B locus, we find that the resistance to proteasome inhibitors
can be overcome by combinatorial targeting.
Our results underline the importance of the p53 and CDK pathways in GBM precision therapy and demonstrate
that an integrated study of primary GBM cells profiled at multiple levels can reveal unexpected associations
between pathways and drug response. The functionally characterized HGCC cell collection provides a resource,
which we expect will enhance and expedite the development of new interventions against GBM.
Results
Patient-derived cell cultures recapitulate the known molecular heterogeneity of GBM
As our model for GBM drug response, we used 100 cultures from our Human Glioma Cell Culture (HGCC)
collection at Uppsala University Hospital in Northern Europe, which underwent systematic genomic and phar-
macological profiling (Figure 1A, Table S1). For these cultures to be a model of GBM diversity, they should
recapitulate several layers of glioblastoma heterogeneity, including molecular subtype, core pathway mutations,
and chromosomal aberrations. We, therefore, established genomic background data for our cell cultures on sev-
eral genomic platforms, which were compared to the corresponding molecular data from surgical GBM samples
in The Cancer Genome Atlas (TCGA) (Brennan et al., 2013). Our primary cultures corresponded well to TCGA
in terms of patient age, survival times, patient sex and molecular subtype (classical/proneural/mesenchymal
system (Verhaak et al., 2010)) (Figure 1B). Our cultures also shared the spectrum of driver genes observed in
TCGA at similar frequencies (Figure 1C, R=0.82) and each culture retained genetic similarity to its source tu-
mor (median of 27 mutations in common; 90% CI=18.5-31.75) (Figure S1A-B). We noted a slight reduction in
the gene copy number of EGFR locus amplification, (Figure S1C-D), which we interpret as loss of extrachro-
mosomal EGFR amplified genetic material unevenly distributed in mitosis as double minutes (Nikolaev et al.,
2014). Still, the overall correlation of DNA copy number aberrations between our cell cultures and TCGA,
however, was very high (R2=0.93) (Figure S1E-F). From this analysis, we conclude that our extended HGCC
panel of primary cultures is genetically representative of GBM diversity as observed across patient tumors.
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Accordingly, pharmacological profiling of a large sample of diverse primary cells should reveal informative
associations to drug response.
Sensitivity to proteasome inhibitors defines two subclasses of GBM cells
To explore the drug sensitivity of primary GBM cultures, we first implemented a discovery screen to select
drugs for subsequent analysis across all 100 cultures. The discovery screen (Figure 2A, Phase 1) was carried
out using a library of 1544 annotated drugs, relevant for both oncology and other disease areas. Applying the
library to 9 GBM cultures of different subtypes, we identified the drugs that reduced viability in at least 3/9
cultures. These hits were compiled into a 248 drug library for profiling the GBM cultures in our collection. We
carried out drug profiling in two phases, with 52 cell cultures each (Figure 2A, Phase 2-3). Drugs retained for
phase 3 were the ones with the highest variability in viability response between cases. As determined by drug
target databases (Drug Repurposing Hub and STITCH5), the library used had broad representation, covering
430 known drug targets, 118 mechanisms-of-action, and 21 disease areas (Figure 2A-B, Table S2). Among
the 30 most active compounds, 9 were previously unreported as candidates for GBM therapy (Table S2).
In each GBM culture, the effect of a drug was summarised as an Area Under the dose-response Curve (AUC)
score. Arranging these scores as a matrix of patient-derived cells (rows) and drugs (columns), we used hier-
archical clustering to detect groups of cell cultures and drugs with strongly correlated behavior (Figure 2C).
Notably, the best-fitted clustering robustly separated the cell cultures into two clusters, defined by sensitivity or
resistance to a single class of drugs; proteasome inhibitors targeting PSMB5 and other proteasome units (Fig-
ure 2C). Graphing the dose-response curves for the six proteasome inhibitors in the data highlights the bimodal
response to this category of drugs (Figure 2D). In our clustering of compounds, several drug targets other than
the top hit PSMB5 (p=2.99 ∗ 10−9) were non-randomly distributed across clusters, such as the dopamine re-
ceptor (DRD2, p = 5.71∗10−3), the muscarinic receptor (CHRM1, p = 5.97∗10−4), spindle poisons (TUBB,
p < 1 ∗ 10−10), and BMP2 (p = 5.24 ∗ 10−6, all p-values corrected by Benjamini-Hochberg’s (BH) method).
Drugs targeting kinases EGFR and PDGFRA, which were strongly enriched as active against GBM cultures
in the first screen (p<1 ∗ 10−5, BH-corrected, Figure 2A), did not exhibit such a significance, indicating that
these are not the most promising candidates for therapy directed against specific GBM subgroups. Of note, we
did not find a significant overlap between clusters of cell cultures and existing transcriptional subtypes. Also,
unlike a recent report on sex differences in drug response (?), our data did not support that the drug sensitivities
measured in our cohort were dependent on patient sex.
This analysis established that patient-derived GBM cells are primarily grouped by their sensitivity to protea-
some inhibitors, and secondarily grouped by response to other classes of drugs. Since we found no evidence of
an association between this grouping and obvious covariates such as GBM subtype or patient sex, we went on
to investigate the data using an unbiased machine learning approach to identify associations between molecular
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data and drug response.
Network analysis links proteasome inhibitors to the p53 pathway
Integrating the collected data, we constructed statistical network models of drug responses in the GBM cells,
with two specific goals in mind. First, we aimed to understand how activation of cellular pathways related
to drug response. Second, we aimed to define how well different classes of compounds can be predicted. To
address the first problem, we computed the association between responses to individual drugs and 50 Hallmark
pathways, using Gene Set Enrichment Analysis (GSEA), retaining drug-pathway associations with q-value
< 0.1. We subsequently used information in the Drug Repurposing Hub database (Corsello et al., 2017) to
group our compounds based on mechanism-of-action (MOA) and used a Fisher test to find strong associations
between pathways and MOAs. We summarised the result as a network in which links are pathway-to-MOA
links with p-value < 0.05 (Figure 3A). The network linked proteasome inhibitors to the expression of p53
Hallmark genes, which was the most enriched Hallmark pathway in this regard (p=0.0043, Fisher’s exact
test with FDR correction). In total, 51 links were detected, containing both known relationships (e.g. between
kinase inhibitors and cell cycle checkpoints) and interesting predictions (e.g. between sigma receptor inhibitors
and lipid metabolism)(Figure 3A).
Accurate prediction of drug responses in primary GBM cells
In extended network analyses, we asked if additional layers of genomic data (e.g. mutations or DNA methyla-
tions) were associated with drug response and if the effect of different drugs could be predicted with accuracy,
based on specific biomarkers. For this, we used a machine learning method, in which drug response (AUC) was
the predicted variable, and other data were used as covariates. For an unbiased search, we let two well-defined
algorithms (random forest and elastic net) select variables from RNA, CNA, and other data types to predict
each individual drug. We used the leave-one-out cross-validation correlation (CV-R) as a metric of predictive
power, which estimates the ability of the collected data to predict prospectively the variation in response in
unseen cases on a scale from 0 (no predictive power) to 1.0 (perfect predictions). Other versions of cross-
validation, like leave-10-out, gave highly correlated results (Methods). Previous versions of this approach have
been successfully evaluated for cell cultures of mixed lineage origins (Kutalik et al., 2008; Barretina et al.,
2012; Garnett et al., 2012; ?; Basu et al., 2013; Seashore-Ludlow et al., 2015; Iorio et al., 2016). However,
there is so far limited experience of the performance of machine learning in a well-characterized cohort of
primary GBM lines.
In primary GBM cultures, a majority of drugs (262) could be predicted at a CV-R greater than 0.33, with
remarkably high CV-R for particular drugs, such as clomipramine (CV-R=0.76). Prediction power depended
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on the drug category. For instance, proteasome inhibitors had a higher average predictive power (CV-R=0.44)
than inhibitors of the tyrosine kinases EGFR, VEGFR and PDGFR (CV-R 0.37 to 0.41) (Table S3). The
machine learning algorithm identified an association between several members of the p53 Hallmark pathway
(CDKN1A, SESN1) and the six different proteasome inhibitors (bortezomib, oprozomib, carfilzomib, MG-132,
delanzomib, ixazomib) (Figure 3B). Consistent with the GSEA result, the number of network connections
between proteasome inhibitors and p53 pathway genes was higher than expected by random, taking into ac-
count the size of the p53 pathway (Fisher’s exact test, FDR-corrected p value=0.0206). This suggests that a
handful of markers in the p53 pathway can guide precision targeting using proteasome inhibitors. To further
corroborate our cross-validation approach, we predicted the drug response in 10 cell cultures that were unseen
by the algorithm, collected in a different hospital and profiled in a different center, and confirmed a differential
response to bortezomib, measured by AUC (Figure 3C).
These analyses establish that drug responses of primary glioblastoma cells can be associated to hallmark path-
ways and predicted with accuracy. The CV-R score of individual drugs (Table S2 and Discussion) is an indica-
tion of that drug’s potential for use in specific GBM subpopulations, and several drugs with high CV-R remain
to be investigated as GBM therapies (Discussion). The best drug response predictions for primary GBM cells
were often based on multiple markers, often from two or more types of genomic data (Figure S3A-B). Machine
learning-based predictions were more accurate (higher CV-R on average) than corresponding predictions based
on transcriptional subtype, clinical data, or mutation/expression of the drug target (Figure S3D-E).
An axis of mutually exclusive TP53 and CDKN2A/B mutations in GBM
The association between drug response class and the p53 pathway motivated further analysis of genetic lesions
in this pathway in our cell lines. Gliomas are known to have different lesions affecting the p53 core pathway,
ranging from mutations affecting p53 itself to indirect de-regulation via amplification of MDM2, or deletion
of the CDKN2A/B locus (Figure 1C). The primary mechanism by which CDKN2A/B deletion affects p53 is
through the loss of the CDKN2A gene product p14(ARF), a protein that blocks MDM2. Other gene prod-
ucts encoded by the CDKN2A/B locus are p16/INK4A and p15/INK4b, both of which block cyclin-dependent
kinases (CDKs) (Tao and Levine, 1999).
To visualize genetic variation in the p53 pathway we applied a principal component analysis. Sorting our
HGCC lines (Figure 4A) and TCGA (Figure 4B) along the first component of variation placed each case
along an axis, defined by gradual changes in p53 pathway gene expression and mutual exclusivity between
p53 mutation and CDKN2A/B deletion (Fisher’s test p=0.0169 and p=6.4401e-05) (Figure 4A,B). The analysis
thus clarified that transcripts selected by our network algorithm (Figure 3) are mostly expressed in CDKN2A/B
deleted cells with wild-type p53, and underlined that both cell cultures and surgical samples from gliomas can
be categorized along a genetic and transcriptional axis, defined by mutually exclusive p53 and CDKN2A/B
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aberrations.
To explore if this distinction was also observed at the protein level, we measured a 192 protein profile in two
p53 mutated and two CDKN2A/B deleted cell lines, by multiplexed proximity extension assays. We found a
significant correlation between RNA and protein expression differences (p < 10−7) and noted p53 itself and the
direct p53 target CDKN1A (p21) as the main differentially expressed gene products (Figure 4C). Consistent
with a loss of p15 and p16, the CDKN2A/B deleted cultures expressed higher levels of two cyclin proteins,
indicating that these cell lines also have a large population of cells with activated cyclin-CDK complexes
committed to cell-cycle entry or mitosis (Figure 4C).
The p53-CDKN2A/B axis orchestrates the proteasome inhibitor response
Next, we asked how the observed variation in p53 and CDKN2A/B affects the response to proteasome inhibitors
in GBM cells. Based on the above analysis (Figure 4) we selected a set of 10 HGCC cultures, with represen-
tative variation in the p53 gene signature, and with different mutation statuses of P53 and CDKN2A/B (Figure
5A). Among the 10, four were identified as p53 mutated by whole-exome and Sanger sequencing (Table S4),
and three (U3054MG, U3173MG and U3180MG) were unable to induce p21 protein, confirming the loss of
p53 function (Figure S4B).
To get a global overview of how cellular pathways are impacted by proteasome inhibition, we first compared
the transcriptional response following bortezomib treatment (10nM, 6hrs) in one sensitive (U3013MG) and one
resistant (U3180MG) cell line (Figure 5B). In both of the cell lines, proteasome inhibition induced unfolded
protein response (UPR), ROS and p53 hallmark pathways in both lines and suppressed cell cycle promoting
genes, but the resistant line showed a statistically stronger induction of genes involved in DNA damage response
(DNA repair and ROS response) and in G2/M checkpoint regulators (Figure 5B). This suggested that resistant
lines might differ in their ability to buffer ROS following proteasome inhibition, and in the activity of DNA
repair pathways.
To explore these differences, we measured to what extent bortezomib-induced the level of ROS in each of the
cell lines, as determined by the CM-H2DCFDA fluorometric assay as an indicator for ROS. Notably, the level
of ROS induction was inversely proportional to the p53 signature (Figure 5C). The induction of ROS was
also concomitant with elevated oxidized glutathione ratios (GSH/GSSG, Figure 5D), higher levels of Caspase-
dependent apoptosis (Figure 5E) and accumulation of ubiquitinated protein in the sensitive lines (supplement
Figure S4C), suggesting ROS-mediated apoptosis as a key effector mechanism (c.f. (Ling et al., 2003; Strauss
et al., 2007)). Consistent with this hypothesis, blocking ROS by anti-oxidants protected cells against borte-
zomib, and elevating ROS by proteotoxic stress using heat shock aggravated the response (Figure S4D). A
number of p53-dependent ROS-suppressive genes were induced selectively in the resistant cells, as determined
by quantitative PCR, including SESN1 (Budanov, 2011), NFE2L2 (Ahmad et al., 2016) and TIGAR (Bensaad
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et al., 2006), potentially explaining the effect (supplement Figure S4A).
To assess differences in DNA repair, we stained two p53-mutant and twoCDKN2A/B deleted cultures for 53BP1
protein following bortezomib treatment (Figure 5F). We noted a significantly higher number of 53BP1 foci in
resistant cell lines, both at basal levels and following 30 min bortezomib treatment indicating higher activity
of the NHEJ DNA repair pathway (Unpaired two-tailed t-tests <0,0001 both at basal level and after treatment
Figure 5F,G). Despite the induction of p21 protein in several of the cell lines (Figure S4B), there were no signs
of p21 induced G1 arrest. Rather, both the sensitive and resistant glioblastoma lines respond to bortezomib
treatment by G2/M arrest (Figure S5). The sensitive lines, however, reduced their S-phase population 2.9-3.1
fold as compared to 1.3-1.8 fold following 10nM bortezomib treatment (Figure S5) alongside an increased
proportion of cells in apoptosis (Figure 5E).
We conclude that in both p53 mutant and CDKN2A/B deleted glioblastoma cells, proteasome inhibition leads
to G2/M arrest and ROS-dependent apoptosis. However, the quantitative balance between these outcomes is
different, the more resistant cell lines are less prone to apoptosis, and show signs of lower ROS induction and
higher DNA repair activity.
The TP53-CDKNA2/B axis determines in vivo bortezomib response
Next, we asked if the variation in p53 and CDKN2A/B aberrations would also affect the in vivo response
to proteasome inhibition. To answer this, we evaluated 9 of the above cell lines in a transplantation based
model of drug response, the chicken chorioallantoic membrane (CAM) assay (DeBord et al., 2018). Using
GFP-luciferase tagged derivatives of each cell culture, we measured bioluminescence 3 days and 5 days post-
inoculation onto the CAM (Figure 6A). When grown on the CAM, treatment by the proteasome inhibitor
bortezomib reduced the growth of some, but not all the primary GBM cultures, at concentrations that were
tolerated by the chick embryo (5-10 µg/kg). The change in bioluminescence following proteasome inhibitor
treatments agreed with the original drug screen results for the 9 cell lines (r=0.73, p=0.0189) (Figure 6B) and
with the p53 gene signature score of the transplanted cell cultures (r=0.65, p=0.0419) (Figure 6C). To explore
these results in an independent model, we compared mice injected into the flank with a sensitive (U3013MG)
and a resistant (U3008MG) cell culture showed significant (p=0.00682), reduction of tumor growth rate only
for the former (Figure 6E). These two experiments established that the variation observed in the initial drug
screen was replicated in vivo.
Potentiating the proteasome inhibitor responses in glioma cells
Our observation that a subset of cell lines was less sensitive to proteasome inhibition motivated us to search for
additional drugs that can be used to overcome proteasome inhibitor resistance. Pharmacologically, such drugs
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should meet the criteria of synergism when combined with a proteasome inhibitor in glioblastoma cells. To
explore this possibility, we selected a set of 25 drugs in different categories (Figure 7A) including (i) activators
of p53, (ii) apoptosis modulators, (iii) kinase inhibitors against RTK and CDK pathways, (iv) compounds that
were statistically selected based on their anti-correlation with bortezomib, (v) compounds that target redox
regulation, and, (vi) compounds that target genes which are selectively upregulated in resistant tumors.
We evaluated each of the 25 drugs using the Combination Index (CI), estimated from a response surface over
a 6x6 matrix of doses, replicated in 4-10 cell lines (Figure 7B). Next, we evaluated if the average CI was less
than 1.0 across all cell lines, thereby indicating that the compound consistently potentiates (i.e. is synergistic
with) bortezomib (Figure 7C). As a second endpoint, we performed a regression test to evaluate if CI depends
on the p53 signature (example in Figure 7D).
13 of the tested compounds potentiated bortezomib in multiple cell lines (Figure 7E). Strong overall synergism
was obtained with two p53 activators, the peptide-based MDM2 blocker PM2 (Spiegelberg et al., 2018) and
the small molecule MDM2 blocker AMG232. By contrast, the mutant p53 selective reactivator PRIMA-1
showed selective single-agent activity in p53 mutant cells but did not potentiate bortezomib (Figure 7E, right
column). Notably, all three apoptosis modulators potentiated bortezomib, as did the CDK2 inhibitor milciclib.
This indicated that higher levels of wild type p53 protein or a lowered apoptotic threshold both suffice to
potentiate bortezomib in primary glioblastoma cells. For 7 of the 13 potentiating compounds, a wild type p53
signature was associated with a lower CI value indicating stronger synergism (Figure 7E). This shows that
bortezomib can be potentiated especially in the more resistant type of cells with wild type p53 and CDKN2A/B
deletion. One exception to this trend was mTOR inhibitor torin-2, which selectively potentiated bortezomib
in p53 mutant cells, which may indicate a differential dependency on this pathway as indicated by our RNA
profiling results (c.f. Figure 5B).
Interestingly, the three compounds selected in a purely data-driven fashion, by virtue of anti-correlation to
bortezomib in Phase 2 and 3 screening data (the calcium channel blocker cilnidipine, the microtubule depoly-
merizing drug nocodazole, and the antibiotic spectinomycin) were all synergistic (Figure 7E, group iv). More
studies would be required to elucidate the mechanism, but we speculate that a common denominator among
all three might be the induction of unfolded protein stress. As an independent test of the synergies, we evalu-
ated two of the selected combinations in a 3D sphere culture system (Figure 7F) and noted significantly lower
viability in spheres treated by bortezomib and navitoclax or milciclib (Figure 7G).
In contrast to the consistent synergism for these drug classes, we found limited evidence that co-targeting redox
pathways would potentiate bortezomib, e.g. NRF2 targeted agent costunolide (Ahmad et al., 2016) (not shown).
We conclude that both Bcl-2 family inhibitors and p53 activators show promise as potentiators of proteasome
inhibitors in glioblastoma cells. Because the potentiating effect is stronger in CDKN2A/B deleted (often more
bortezomib resistant) cell lines, the results suggest a strategy to target also these cells. We also find signs that
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automatically nominated compounds, selected by virtue of their anti-correlation in the screening data, make
good combination partners.
Drug classes and targets with high prediction scores
Discussion
The goal of our study was to identify new opportunities for GBM precision medicine, by an integrated study
of patient-derived GBM cells. Previously, an initial set of 48 glioma cell cultures has been distributed as the
Human Glioma Cell Culture (HGCC) resource (Xie et al., 2015).Extending this collection to 100 cell cultures,
characterised at multiple genomic and functional levels, enabled us to map the association between pathways
and multiple drug classes. The resulting data thus provide a starting point for research investigating drug
repurposing and precision therapy.
As a validation of our resource, we investigate the detected association between mutually exclusive aberrations
in p53 and CDKN2A/B and the sensitivity to several proteasome inhibitors. The impact of mutations in the
tumor suppressor p53 and CDKN2A/B loci on the efficacy of proteasomal remains to be fully understood. On
the one hand, p53 is identified as one major mechanism underlying the effect of proteasome inhibitors because
proteasome inhibition can induce apoptosis through stabilization of p53 protein (Xue et al., 2019). On the
other hand, proteasome inhibitors can also be highly effective against p53 mutant cell lines of various tissue
origins, such as glioma (Seol, 2011), epithelial carcinomas (Dabiri et al., 2017; Adams et al., 1999; ?; Qiang
et al., 2017), blood malignancies (Strauss et al., 2007; Hideshima et al., 2001). Suggested mechanisms for this
include p53-independent induction of p73 (Dabiri et al., 2017), and induction of apoptosis regulating proteins
such as DR5 (TRAILR2) (Qiang et al., 2017; ?). Of the 10 cell lines that we investigated in detail, 7 had signs
of functional p53, indicated by their ability to induce p21 after genotoxic stress. Less is known about of how
CDKN2A/B deletion affects proteasome inhibitor response, but since it is established that proteins encoded by
the locus (e.g. p16/INK4A) are modulated by the proteasome pathway, such effects are plausible. Taking these
factors into account, the model we propose for the relative resistance to proteasome inhibitors in some GBM
cell lines is that the level of p53 activation stays under a threshold, insufficient to induce apoptosis. This could
be dependent on the increased synthesis of anti-oxidants, e.g. glutathione (Figure 5D) that scavenge reactive
oxygen species and more active DNA damage repair mechanisms in the proteasome inhibitor-resistant cell
lines (Figure 5F,G). Consistent with the proposed model, MDM2 inhibitors PM2 and AMG232 potentiated
the bortezomib response and synergistically killed GBM cells, and all three agents that modulate the apoptotic
threshold, such as navitoclax, potentiated bortezomib. Our results are thus consistent with a role for p53 in the
response to proteasome inhibitors, in line with (?Asklund et al., 2012; Forte et al., 2019) but imply substantial
quantitative and phenotypic differences in the response to proteasome inhibition. Further work, including
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quantitative mathematical modeling, will be needed to elucidate these differences and to chart the relative
contributions of aberrations in p53 and CDKN2A/B, respectively.
The clinical potential of the reported gene signature and combinations remains to be assessed. Among the
publicly disclosed proteasome inhibitors, salinosporamide A (Marizomib) shows promise for CNS tumors, as
it penetrates the blood-brain barrier in rodent models (Di et al., 2016) and is under phase 3 investigation in
humans (NCT03345095). Our proposed classification of glioma cells based on p53 and CDKN2A/B status
has potential applications in the prospective design and post-hoc interpretation of proteasome inhibitor clinical
trials in GBM. Notably, germline mutation of both p53 (Li-Fraumeni syndrome) and CDKN2A (melanoma-
astrocytoma syndrome) are associated with substantial risk increase for brain tumors. We speculate that the
small group of patients with a GBM associated with Li Fraumeni syndrome might be a particularly interesting
group for proteasome inhibitor treatment. The identified combinations provide a framework to study the po-
tentiation of proteasome inhibitors. While many of the detected effects are robust across cells from multiple
patients (particularly for Bcl-2 family inhibitors), more analysis is warranted to assess the efficacy and safety
of such combinations.
In addition to the specific observations related to proteasome inhibitors, our analysis gives interesting general
insights regarding GBM precision therapy. First, we note that the established subtypes (proneural, classi-
cal, and mesenchymal) are relatively weak predictors of drug response, compared to the optimally selected
transcriptional or genetic markers. Also, the best performing biomarkers are not necessarily somatic point
mutations, motivating the use of multiple data layers as a strategy to identify biomarkers for drug response
in GBM cells (Figure S3). Second, the range of drugs whose response can be predicted with accuracy in
primary GBM cells is broader than frequently investigated kinase inhibitors (c.f. Table S3). Drugs with high
predictive performance (high CV-R) and strong effect (low AUC) in a subset of cell cultures are of particular
interest for drug repurposing. Key examples of such drugs in our atlas include calcium modulators (digoxin,
calcimycin (A23187) and niguldipine), three likely anti-metabolites (lycorine, thioguanosine, perhexiline), an
anti-malarial (quinacrine), modulators of dopaminergic transmission (sertindole, 5-nonloxytryptamin), antisep-
tics (hexetidine, chlorhexidine, ciclopirox), and the cyclical peptide thiostreptone, all with high ranking CV-R
scores (Table S2). Accordingly, we propose that the proteins and pathways targeted by these drugs may warrant
further investigation as candidates for stratified therapy of GBM. For instance, quinacrine is a known inhibitor
of phospholipase A2 (PLA2), an enzyme that hydrolyses phospholipids into second messengers that regulate
cell proliferation, cell migration and cell survival through binding of G-protein coupled receptors (?). High
expression of PLA2 has been associated with poor prognosis and therapy resistance in glioma patients (?),
(?). As a second, example, the activity of digoxin and digitoxigenin may imply Na+ -K+ ATPase (ATP1A1)
as a possible target in GBM, or other targets affected by digoxin drugs in GBM cells, such as HIF1alpha and
HIF2alpha (?). Last, we note that more than 80% of the GBM cultures are sensitive to omacetaxine mepesuc-
cinate (homoharringtonine), a blocker of the large 60S ribosomal subunit peptidyltransferase center (?), with
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RPL3 as the possible target (?), suggesting that ribosomal function or biogenesis may be promising targets in
subsets of GBM. Continued integrated analysis of primary cell lines, linked to in vivo assessment, will likely
broaden our perspective on GBM precision therapy even further.
The presented extension of the HGCC biobank presents a valuable resource for GBM precision medicine,
distributed as an open-access cell line library (hgcc.se) with associated databases (portal.hgcc.se) and networks
of biomarker-drug associations, which can be analyzed in Cytoscape (Shannon et al., 2003) or compatible
programs. Users are invited to explore the data and retrieve primary GBM cell lines with known genomic
parameters or drug sensitivity, for functional studies, or for data-driven modeling. Building on early successes
with heterogeneous traditional cell lines (Kutalik et al., 2008; Barretina et al., 2012; Garnett et al., 2012; ?;
Basu et al., 2013; Seashore-Ludlow et al., 2015; Iorio et al., 2016), we expect that an increasing number of well-
characterized and diagnosis-specific data sets will gradually increase both the predictive power, interpretability
and clinical relevance of cell line panels.
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Main Figure Titles and Legends
Figure 1: Study overview and genomic characteristics of primary GBM cultures
(A) Study overview. Based on the integrated profiling of 100 patient-derived GBM cultures, we here develop
network models of drug response, which identify p53 as a key determinant of pharmacological class.
(B) Cohort composition compared to the TCGA; age distribution, sex, survival and transcriptional subtype.
(C) Alterations frequencies of key genes in the p53 and RTK/MAPK pathways, arranged as in (Brennan et
al., 2013) Note the similarity between primary GBM cultures and TCGA surgical samples across core GBM
pathways (R=0.82). (Red indicates amplification or mutation, blue indicates deletion or mutation.)
Figure 2: Defining the global variation of drug response in primary GBM cells.
(A) Structure of the screen. A 1544 drug discovery screen (phase 1) was followed by secondary and tertiary
screens across using focused libraries of drugs with GBM activity (phase 2 and 3). Drugs in our phase 2 library
had 363 known targets, 75 of which were over-represented (empirical p-value less than 0.05) compared to the
phase 1 library, e.g. EGFR, PDGFRA/B (bars).
(B) Drug target annotation of our GBM library, in comparison to recent studies of cancer cell panels. Mechanism-
of-action (MOA), disease indication and target from the Drug Repurposing Hub database.
(C) Two-way clustering of primary GBM cultures (rows) and drugs (columns) based on Area Under the dose-
response Curve (AUC) scores. The GBM cultures were robustly grouped into two clusters that did not correlate
with transcriptional subtype. The drugs were grouped into more than 10 clusters, many of which were enriched
for drugs with a shared target (selected targets discussed in the text).
(D) The AUC of the 6 proteasome inhibitors in our library was markedly bimodal (dashed box) and consistent
across compounds, here shown as dose-response curves.
Figure 3: Network analysis links proteasome inhibitors to the p53 pathway
(A) Drug response in primary GBM cultures correlates, in a drug mechanism-dependent manner, with the tran-
scriptional activity of specific pathways. The network describes statistically supported (p<0.05) associations
between drug mechanism-of-action (MOA, green circles) and Hallmark pathways in the Molecular Signature
Database (grey boxes). Nodes sizes are proportional to the number of involved drugs and genes, respectively
and line thickness is proportional to −log10(p − value) of the association. The MOA nodes are color-coded
(dark green - yellow) based on their average predictive power (CV-R) (c.f. Table 1).
(B) Machine learning detects biomarkers of proteasome inhibitor response in GBM. The algorithm (bootstrap
elastic net regression) detected a combination of mutations, CNAs, DNA methylation events and transcripts
predictive. Selected transcripts were members of the p53 Hallmark pathway.
(C) The machine learner predicted proteasome inhibitor response in GBM cells from unseen patients. Bar chart:
predicted viability in 20 primary GBM lines from a different hospital (Queen Mary, London). Lines predicted
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to be sensitive (GBM54) and resistant (GBM19) were confirmed in a separate dose-response experiment.
Figure 4: Aberrations of p53 and CDKN2A/B in cell lines and patient samples.
(A) HGCC cultures ordered according to the 1st principal component of the p53 pathway (Methods). Note the
mutual exclusion of p53 and CDKN2A/B aberrations
(B) TCGA surgical samples ordered according to the corresponding 1st principal component.
(C) Differential expression of RNA (y-axis) and protein (x-axis) for 192 genes/proteins, comparing 2 sensitive
vs 2 resistant lines.
Figure 5: Cellular effects of bortezomib treatment in a sample of GBM cells
(A) Sample of cell lines for in-depth functional analysis. The p53 status gradient indicates the first principal
component of the p53 signature. The grey boxes indicate the presence of p53 mutations, CDKN2A/B deletion,
and p21 protein expression (see Supplemental figure S4A).
(B) RNA profiling comparison of one sensitive and one resistant line, measuring the log fold change of tran-
scripts after 10 nM bortezomib for 6 hrs. Enrichment analysis of commonly affected (average fold change
in both lines) pathways and differentially affected (fold change difference) pathways. Fisher’s test with FDR
correction.
(C) P53 signature predicts ROS response. X-axis: p53 signature principal component score as in Figure 4A, Y-
axis relative increase (a.u.) of ROS as measured by a fluorometric assay (linear regression, R2=0.58, p=0.0105).
(D) Redox balance (GSH/GSSG ratio) and (E) apoptosis in bortezomib resistant (n=5) vs sensitive (n=5)
patient-derived GBM cultures. Mann-Whitney U test.
(F) Comparison of induction of 53BP1 NHEJ DNA double-strand break processing and repair in 4 lines by
bortezomib.
(G) Quantification of 53BP1 foci illustrated in (F). Student’s t-test.
Figure 6: The p53/CDKNA2/B axis determines in vivo responses and predicts tumor initiation.
(A) The chorioallantoic membrane (CAM) in vivo assay was used to measure the response to bortezomib in 9
patient-derived cell lines.
(B) Correlation of CAM result and in vitro AUC viability score. X-axis: average proteasome inhibitor AUC
from the drug screen. Y-axis: negative values indicate a stronger reponse to bortezomib treatment.
(C) Correlation of CAM result (y-axis) and p53 signature score (x-axis, defined as in Figure 4A).
(E) Tumor growth rate of flank xenografted sensitive (U3013MG, CDKN2A wt, p53 mut) vs resistant (U3008MG,
CDKN2A del, p53 wt) GBM cells in immune deficient mice, showing a selective bortezomib effect in tumors
from sensitive cells.
Figure 7: Modulation of proteasome inhibitor response of glioma cells.
(A) Based on our integrated data, we tested 25 compounds in combination with a proteasome inhibitor.
(B) Each compound was evaluated across a 6x6 dose-dose-response surface, replicated in multiple cell lines
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with different p53 signature scores.
(C) Combination Index statistics for 25 compounds. X-axis: compounds. Y-axis: statistical spread of CI for
tested patient-derived cell lines. Points are individual patient-derived cell lines, boxes are 90% confidence in-
tervals.
(D) Test for CI dependency on p53 signature, two linear regression examples, indicating a lower CI for a higher
value of the p53 signature score.
(E) Summary; significant results for endpoint 1 (average CI < 1.0) and endpoint 2 (CI depends on p53 sig-
nature) are shaded. Arrows indicate a positive (up) or a negative (down, as in (C)) dependency on the p53
signature.
(F) Sphere model to evaluate bortezomib in combination with navitoclax in one bortezomib-sensitive (U3013MG)
and one resistant line (U3008MG). Bars = 800 µ. (G) Sphere size is significantly affected by bortezomib and
navitoclax treatment. Red bar = observed sphere size after combination treatment. Dashed bar = expected





Further information and requests for resources and reagents should be directed to and will be fulfilled by the
Lead Contact, Sven Nelander (sven.nelander@igp.uu.se).
Materials Availability
Individual cell lines can be obtained following establishment of a Material Transfer Agreement. Contact the
Human Glioma Cell Culture biobank administrator at mail@hgcc.se, or the Lead Contact. GFP-tagged versions
of the cell lines used in the CAM experiments are obtained using the same procedure.
Data and Code Availability
Individual genomic data types are made available at portal.hgcc.se. The gene expression data is also distributed
via the Gene Expression Omnibus repository as GSE152160. Code for computational analyses are available
from the Lead Contact.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Tumor sample collection was approved by the Uppsala regional ethical review board, number 2007/353; in-
formed consent was obtained from all subjects included. The cell line designations and key data (sex, age,
survival) of each subject are listed in Table S1.
METHOD DETAILS
Cell culture collection methods
Primary cultures were derived from tumor samples in defined serum-free neural stem cell (NSC) medium, sup-
plemented with B-27, N2, EGF, FGF, on laminin-coated Corning™ Primaria™ Cell Culture plates (Thermo
Fisher Scientific, Waltham, MA) as described (Xie et al., 2015), and GBM cells (Table S1) were subsequently
grown in this medium. The cell cultures for the drug screening assay were between passage 8 and 24 (av-
erage 16). As reference cell lines, we used human immortalized astrocytes (Arne Östman, Karolinska In-
stitutet), HepG2 (Bo Lundgren, Stockholm University) and human foreskin fibroblasts 1523 (Karin Forsberg
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Nilsson, Uppsala University). References cells were grown as adherent cultures in DMEM culture medium
(Invitrogen, Carlsbad, CA) supplemented with 1% L-Glutamine (Sigma-Aldrich, St. Louis, MO), 1% Peni-
cillin/Streptomycin (Sigma-Aldrich), 1% Gibco MEM Non-Essential Amino Acids (Thermo Fisher Scientific)
and Gibco 10% fetal bovine serum (Thermo Fisher Scientific). H9-derived human neural stem cells, propa-
gated as adherent culture in complete StemPro® NSC SFM (A1050901, Thermo Fisher Scientific) according
to manufacturer instructions were also included as a reference.
Genomic profiling of patient-derived GBM cultures
Genomic profiling of the GBM cell lines (Figure 1C, Figure S1) was conducted at Science for Life Labora-
tory core facilities (scilifelab.se) and the Uppsala Academic Hospital Array and Analysis facility. DNA was
amplified from cell lines using the DNeasy Blood and tissue kit, Qiagen. DNA copy number aberrations were
measured using Affymetrix Cytoscan HD arrays (Thermo Fisher Scientific) in accordance with the manufac-
turer’s instructions (Affymetrix® Cytoscan User Guide (P/N 703038 Rev4.). Chromosomal segments carrying
altered numbers of copies was estimated using the Patchwork R package (Mayrhofer et al., 2013), which quan-
tifies the log-relative change in DNA content for each chromosomal region. DNA whole exome sequencing
of cell lines was performed using Ion Torrent sequencing as follows. 100 ng of genomic DNA, amplified ac-
cording to Ion AmpliSeq™Exome Library Preparation protocol (Thermo Fisher Scientific). Adaptors (Ion P1
Adapter and Ion Xpress™Barcode Adapter, Thermo Fisher Scientific) were then ligated to generate sequencing
libraries, which were purified using Agencourt® AMPure® XP reagent (Beckman Coulter) and eluted in ampli-
fication mix (Platinum® PCR SuperMix High Fidelity and Library Amplification Primer Mix, Thermo Fisher
Scientific) and then amplified. Size-selection and purification was conducted using Agencourt® AMPure®
XP reagent (Beckman Coulter). Emulsion PCR was performed on the Ion OneTouch™2 system using the
Ion PI™Template OT2 200 Kit v3 (Thermo Fisher Scientific). Samples were loaded on Ion PI™chips v2
and sequenced on the Ion Proton™System using Ion PI™Sequencing 200 Kit v3 chemistry (Thermo Fisher
Scientific). Data were analyzed and with the Torrent Suite Software (Thermo Fisher Scientific). Follow-
ing alignment to the hg19 reference genome using BowTie, we computed somatic variants using Torrent
Suite, SomaticSniper (Larson et al., 2012), VarScan2 (Koboldt et al., 2012) and MuTect 2 (Cibulskis et al.,
2013) using default settings. We annotated the variants using ANNOVAR (Wang et al., 2010) and dbsnp138
(https://www.ncbi.nlm.nih.gov/projects/SNP/). The calls were aggregated across the four callers and a gene
was considered mutated (1) if it met the criteria of (i) being found by at least 3 callers, (ii) was annotated
as nonsynonymous, and (iii) not present as germline variants in the 1000 genomes project (1000 Genomes
Project Consortium et al., 2015) above 2 percent prevalence according to ANNOVAR. DNA methylomes were
measured on Infinium® MethylationEPIC BeadChip Infinium arrays (Illumina, San Diego, CA), in accordance
with the Infinium® HD Assay Methylation protocol (Illumina). Quality control of the generated data was per-
formed using the methylation module of the GenomeStudio® v2011.1 data analysis software (Illumina) and by
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use of the BeadArray Controls Reporter software (Illumina) to analyze the sample controls. From the primary
data, probe specific β values, for 850,000 probes were computed as the probe-specific methylation fraction.
RNA profiling was performed using Affymetrix HTA 2.0 arrays according to manufacturer recommendations,
normalized to gene level using the Affymetrix Power Tools version 1.19.0 (http://www.affymetrix.com). The
resulting gene expression data were normalized using the naiveReplicateRUV method (Gagnon-Bartsch and
Speed, 2012) with negative control genes defined as in (Eisenberg and Levanon, 2003).
Pharmacological profiling of patient-derived GBM cultures
Large-scale measurements of drug responses (Figure 2) were carried out at the Science for Life Laboratory
Drug Discovery and Development platform. Cells were seeded one day prior to treatment using a Multidrop
384 liquid dispenser (Thermo Fisher Scientific) in laminin-coated 384-well microplates (BD Falcon Optilux
#353962), at a density ranging from 2000-4000 cells per well to ensure subconfluent growth phase (approx-
imately 70%) at the end of the assay. For the initial screen in 9 glioblastoma cell cultures (Figure 2A) we
tested 1544 unique compounds from the Screen-Well® kinase inhibitor library (BIOMOL International/Enzo
Life Sciences, Plymouth Meeting, PA, 80 compounds), the NCI DTP Repository (National Institute of Health,
Rockville, MD, 101 compounds), the NIH clinical collection (https://commonfund.nih.gov/molecularlibraries/
tools, 727 compounds), and the Prestwick Chemical Library® (Prestwick Chemical, San Diego, CA, 1200
compounds). Redundant compounds were removed to a total of 1544 compounds. In the subsequent screen
(c.f. Figure 2A) 262 compounds were tested in 11-point dose dilution series (starting at 100µM in Phase 2
and 50µM in Phase 3) and assayed for viability after 3 days of treatment using a Resazurin assay diluted 1:10
in medium as previously described (Page et al., 1993), and detected by a fluorescent plate reader (EnVision
multilabel reader, PerkinElmer). Each plate was subject to quality control comparing fluorescence values of
doxorubicin treated (11 doses, 0-100 µM) cells as positive control and DMSO vehicle (0.1%) as negative con-
trol. All data was normalized against plate DMSO vehicle wells. We scored the sensitivity of each cell culture
to each compound by an Area Under the Curve (AUC) score for the dose-response values. This metric was
used since it gives an interpretable value for all drugs and cell cultures, not only for those with well-defined
IC50. For 183/262 compounds, the IC50 was within the 11 dose range and for an additional 16 drugs, the IC75
was within the dose range used (Table S2).
Functional validation of p53-dependent responses of GBM
Gene signature of p53 activity in GBM, and analysis of p53 status in 10 GBM cultures
For all GBM cultures with available whole-exome sequencing and RNA profiling data (n=62) we computed the
differential expression between p53 mutant and p53 wild type cell cultures, detecting p53 as the main differ-
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entially expressed pathway. The 36 transcripts in the p53 Hallmark pathway that were differentially expressed
(BH adjusted p<0.05) were arranged as a matrix, which was analyzed by PCA, whereby the first principal com-
ponent was used as the p53 signature score of each cell culture (Figure 4A). We selected 10 representative GBM
cultures based on variation in this p53 signature and proteasome inhibitor response (Figure 5A). To confirm
p53 status, we used targeted Sanger sequencing (c.f. . For each of the 10 selected cultures, we amplified DNA
sequences for p53 coding exons as described by Pfaff et al., (Pfaff et al., 2010). The sequencing was performed
as Light run in forward direction by GATC Biotech (Konstanz, Germany) using 5 µl of PCR products and se-
quence alignment was carried out using the SnapGene Viewer 4.1.9 software (GSL Biotech LLC, Chicago, IL)
against the NC_000017.11 TP53 reference sequence. The International Agency for Research on Cancer TP53
database (http://p53.iarc.fr/) was used to determine the significance of identified sequence variants. As a com-
plement to Sanger sequencing, p53 functional status was assessed using an etoposide treatment assay (Figure
S4B), as follows. The selected 10 GBM cell cultures were treated with 10 µM etoposide for 2, 6, 16 and 24
hrs, following lysis in RIPA buffer (Thermo Fisher Scientific) supplemented with cOmplete™ULTRA protease
inhibitor cocktail (Roche, Basel, Schweiz) and phosphatase inhibitors PhosSTOP (Roche). 25 microgram of
lysate was resolved by 4-12% Bis-Tris gradient gel (Invitrogen) in MOPS buffer, transferred onto nitrocellulose
membranes (Invitrogen) and blocked in buffer (5% (wt/vol) BSA or 5% (wt/vol) nonfat milk (Bio-Rad) , TBST
(TBS, pH 7.4, 0.1% Tween-20) for 1 hr at room temperature. Primary antibodies used were p21 rabbit antibody
(12D1, Cell Signaling Technology) (1:1000 in 5% BSA, TBST), beta-actin mouse monoclonal antibody (C4,
Santa Cruz) (1:1000 in 5% milk, TBST) and cyclophilin rabbit polyclonal antibody (ab16045, Abcam) (1:2000
in 5%milk/TBST). Following overnight incubation of membranes with primary antibody at 4°C. HRP-linked
secondary antibodies were diluted in blocking buffer; donkey anti-rabbit (GE Healthcare, Chicago, IL) (1:5000
in 5% BSA), goat anti-mouse (GE Healthcare) (1:5000 in 5% milk), and incubated for 1 hour at room tempera-
ture. Blots were developed by AmershamTMECL SelectTM western blotting detection reagent (GE Healthcare),
and visualized using ImageQuant LAS 4000 (GE Healthcare) biomolecular imager.
RNA profiling and GSEA
For Figure 5B, we used RNA sequencing using the method in (Almstedt et al., 2020) to profile U3013MG
and U3180MG cells after 6 hrs treatment by bortezomib, marizomib and delanzomib at 10nM (n=3 technical
replicates for each treatment). Vehicle treated cells were used as replicates (n=3 technical replicates). We used
Fisher’s test with FDR p value correction to test for overlap between Hallmark pathways and genes that were
either upregulated in both cell lines (average fold change in both) or selectively up in U3180MG vs U3013MG
(fold change in U3180MG cells minus the fold change in U3013MG cells).
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Responses to proteasome inhibition in 10 GBM cultures with different p53 status
To measure the effects of proteasome inhibition, we used qPCR, western blot and proximity extension assays
as follows. For Figure S4A, we selected a panel of genes for qPCR validation. Selection was based on whether
(i) they were a marker in our network analysis, (ii) they were a known p53 target or (iii) involved in other
key pathways. 10 GBM cultures were seeded into 6 well plates and were treated with DMSO vehicle or 10
nM Bortezomib A panel of 10 GBM cultures with different proteasome inhibitor sensitivity were treated with
10nM bortezomib (PS-341, #S1013, Selleck Chemicals, TX, USA) or vehicle (0.1% DMSO) for 6 hrs and
24 hrs in triplicates. Total RNA was isolated using the phenol/chloroform method with TRIzol LS Reagent
(#10296010, Thermo Fisher Scientific) and 500 ng of total RNA was then transcribed using iScriptTM gDNA
Clear cDNA Synthesis Kit (Bio-Rad, Hercules, CA, US) and diluted in sterile water to a concentration of 1.875
ng/µl. Quantitative PCR was carried out on a CFX384 TouchTM Real Time PCR Detection System (Bio-Rad),
using SsoAdvancedTM Universal SYBR™Green Supermix (#1725275, Bio-Rad) in duplicates in a total reac-
tion volume of 10 µl, using primers in (Table S5). Gene expression was normalized using 3 reference genes
(RPS18, GAPDH, RLP13A) and calculated with qBase MSExcel VBA applet (Hellemans et al., 2007). To
analyze protein turnover in treated vs untreated resistant and non-resistant cells (Figure S4C), we analyzed
detergent soluble and insoluble fractions, for enrichment of aggregated protein (Miyahara et al., 2016; Moriya
et al., 2015) after 24 hours of bortezomib treatment, by western blot detection of ubiquitin (P4D1, Cell Sig-
naling Technology, Inc., Danvers, MA, 1:1000 in blocking buffer) with b-actin (C4, Santa Cruz, Dallas, TX,
1:10000 in blocking buffer) as a loading control. Blots were developed and visualized as described above.
To quantify glutathione ratios and caspase activity following bortezomib treatment (Figure 5D, E), we used
the GSH/GSSG-Glo and Caspase-Glo 3/7 assays (Promega, Madison, WI) respectively. Proteome alterations
were measured on proximity extension assay (PEA) arrays (Olink Proteomics, Uppsala, Sweden), using two
panels targeting proteins involved in cancer-related pathways and cellular processes. Each PEA panel included
192 assays targeting proteins and four spike-in controls consisting of two recombinant non-human proteins as
incubation controls, an extension control, and a PCR detection control. We used log fold change values to
search for proteins changed by proteasome inhibition in resistant and non-resistant cells and to compare levels
of proteins and corresponding mRNAs in untreated cells (Figure S4E).
Details of Proximity Extension Assay Analysis
Cell cultures U3013MG, U3054MG, U3008MG, and U3213MG were seeded at 15,000 cells per well in two
replicate 96-well plates [Greiner Bio One cat#655986]. Twenty-four hrs later, bortezomib was added at a
final concentration of 1 nM, 6 nM, 10 nM or 0.2% DMSO as vehicle control. At 24 hrs post-drug exposure, the
replicate plates were gently washed 1X with PBS (37°C). Subsequently, the cells in one 96-well plate were fixed
at room temperature for 10 min with a mixture of 2% PFA, 0.1% Triton X-100 and 10µg/ml Hoechst stain. The
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fixed cells were to enumerate the number of cells per well per corresponding treatment regimen. The cells in the
second plate were lysed with 25µl ice-cold lysis buffer/well (1% NP-40, 0.1% Triton X-100, 0.1% sulfobetaine,
150 mM NaCl, Protease Inhibitor Cocktail cOmplete™mini (Roche), TE pH 8). Following the addition of the
lysis buffer, the plate was briefly vortexed, centrifuged for 1 min, 4°C at 1000 rpm, and then stored at -80°C
until use. The cell lysates were analyzed for relative protein expression using two non-commercial, exploratory
multiplex proximity extension assay (PEA) panels (Olink Proteomics). The two panels target proteins involved
in cancer-related pathways and cellular processes (e.g. cell cycle) respectively. Each PEA panel includes
92 assays targeting proteins and four spike-in controls consisting of two recombinant non-human proteins as
incubation controls, an extension control (ExtCtl) and a PCR/detection control. Briefly, 2µl cell lysate was
mixed with 3µl multiplex PEA probe mix. The mix contained 0.3µl of each the PEA A- and B-oligonucleotide
conjugated antibody probes (final antibody-conjugate concentration of 100 pM), 0.2µl Incubation Stabilizer
(Olink Proteomics), and 2.1µl Incubation Solution (Olink Proteomics). Each analysis plate included 8 replicate
lysis buffer-only negative controls. The plates were briefly centrifuged, sealed, and incubated overnight at 4°C.
Following overnight incubation, plates were briefly spun down, and 96 ml of a PEA probe extension mix was
added to each well. The mix contained 0.2µl PCR Polymerase, 0.5µl PEA Enzyme, and 10µl PEA Solution
(all Olink Proteomics) and 85.3µl molecular grade water. Plates were sealed, gently vortexed, spun down, and
then placed in a thermal cycler for the extension reaction (50°C, 20 min) and pre-amplification of extended
PEA probes via universal primers (95°C, 5 min; 95°C, 30 s; 54°C, 1 min; and 60°C, 1 min) for 17 cycles.
The pre-amplified DNA molecules from the multiplex detection reaction were decoded and quantified using
a Fluidigm 96.96 Dynamic Array Integrated Fluidic Circuit on a Biomark HD system. 2.8µl of each sample
was mixed with 5µl Detection Solution, 0.071µl Detection Enzyme, and 0.028µl PCR Polymerase (all Olink
Proteomics) and 2.1µl molecular grade water. 5µl of each sample plus detection mix was loaded into a primed
96.96 Dynamic Array IFC (right inlets). 5µl of each of the 96 primer pairs (Olink Proteomics), designed to
amplify individual target-specific DNA reporter sequences generated in the PEA reactions, was also loaded in
the Dynamic Array (left inlets). The chip was placed in Fluidigm’s IFC HX according to the manufacturer’s
instructions and then run in Fluidigm’s Biomark with the following settings (Gene Expression application,
ROX passive reference, single-probe assay with FAM-MGB probe) and protocol: thermal mix (50°C, 120 s;
70°C, 1,800 s; 25°C, 600 s), hot start (95°C, 300 s), and PCR cycling for 40 cycles (95°C, 15 s; 60°C, 60
s). BioMark generated PEA output files were processed to flag data points where the ExtCtl was smaller or
greater than two standard deviations from the ExtCtl sample mean. The remaining Ct values were normalized
as follows: for each sample, the Ct value of the ExtCtl was subtracted from the Ct value of the protein analyte
yielding dCt values. Then, for each assay, the dCt values were subtracted from a negative control background
value computed as the mean - 3*SD of the lysis buffer only negative control values. This ensures that observed
signals for each assay in the presence of a cell are at least 3 standard deviations away from any signals observed
in the absence of any antigen. All resulting values below zero were set to zero, and the signal was deemed
undetected. The data are presented in (Figure 4C, S4E).
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p53 targets and ROS levels in proteasome inhibitor-treated GBM cultures
To measure the level of reactive oxygen species before and after treatment (Figure 5C), we seeded GBM cells
to Corning 96-well black wall plates at the concentration of 10.000 cells per well in NSC medium where B27
supplement was replaced with B27 Supplement, minus antioxidants (10889-038, Thermo Fisher Scientific).
After overnight incubation, cells were treated with etoposide (10, 30 and 50 µM) and bortezomib (10 nM) for
30 hrs. For assessment of general reactive oxygen species, cell-permeant fluorescent probe CM-H2DCFDA
(#C6827, Thermo Fisher Scientific) was used at 2.5 µM final concentration, and cells were imaged by an
IncuCyte® S3 live-cell imaging system (Sartorius, Göttingen, Germany) (10x objective, 3 biological replicates
x 4 technical replicates). Acquired images were analyzed with the IncuCyte® inbuilt software to determine
average green mean object intensity (GCU). The experiment was performed in three biological replicates in a
panel of ten GBM cell cultures.
Glutathione ratio and Caspase 3/7 assays.
We measured bortezomib-induced cellular stress (Figure 5D) using the luminescence-based GSH/GSSG-Glo
assay (Promega). Both oxidized and total glutathione levels were obtained and used to calculate the ratio of
reduced to oxidized glutathione. Cells were seeded at 5,000 cells/well. After 24 hours, cells were treated
with either the drug bortezomib at 10 nM or the vehicle for 72 hours. Triplicate wells were used per condition.
Luminescence was measured following the manufacturer’s instructions, and background values were subtracted
from all measurements. The ratios of GSH/GSSH were calculated for vehicle and control-treated cells. To
measure Caspase 3/7 activity (Figure 5E), cells were seeded overnight at 5,000 cells/well in laminin-coated
96-well Primaria plates in standard NSC medium. Cells were then incubated for 48 hours with bortezomib
(10 nM), the corresponding DMSO concentration, or left untreated. Triplicate wells were used per condition.
Viability assay was performed using the alamarBlue® cell viability reagent. Measurement of caspase 3 and 7
levels was performed using the Caspase-Glo® 3/7 Assay detection assay kit (Promega) following manufacturer
recommendations. As above, cells were seeded overnight in a white-walled 96-well plate at 5.000 cells/well
following incubation for 48 hrs in triplicate with bortezomib (10 nM), vehicle or left untreated. An equal
volume of reconstituted Caspase-Glo Reagent was added to each well and luminescence was measured after
30 min incubation. Background luminescence was subtracted. The amount of Caspase 3/7 was then calculated
relative to cell viability for each cell culture.
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In vivo validation of differential proteasome inhibitor responses in GBM
Chicken chorioallantoic membrane assay
For Figure 6A-C, fertilized White Leghorn chicken eggs were obtained within a week after laying (LSK Poultry
Oy, Laitila, Finland). The highest non-toxic dose of bortezomib was established to be approximately 10 µg/kg.
On EDD 7, 1x106 glioblastoma cells were transplanted onto the CAM in 20 µ50% MatrigelTM (#11543550,
Fisher Scientific) and PBS suspension (Supplement). On EDD 10, we recorded bioluminescent (BLI) signal
using an IVIS Spectrum camera (PerkinElmer) and applied vehicle (0.01% DMSO) or bortezomib (5 or 10
µg/kg) topically on the CAM. On EDD 12, IVIS imaging was repeated and embryos were euthanized. BLI
signal was analyzed using Living Image 3.2.0 (PerkinElmer) software and we used linear regression to estimate
the log fold IVIS signal per µg/kg unit of treatment, with data from n=322 eggs in total.
Mouse xenotransplantation and bortezomib treatment
All mouse experiments were performed in compliance with an ethical permit granted by the Uppsala Animal
Research Ethical Board, number C41/14. 7 week-old Balb/cAnNRj-Foxn1nu/Foxn1nu female mice (Janvier
Labs, Le Genest-Saint-Isle, France) were injected with U3013MG cells cultured adherently, U3013MG cul-
tured as spheres and U3008MG cultured as spheres. When tumor volume exceeded 0.1 cm3, mice were ran-
domized into groups treated with bortezomib (0.5 mg/kg; n=14) or vehicle (DMSO; n=8). After tumor induc-
tion with PI-sensitive and PI-resistant glioblastoma cell cultures, mice were monitored at least twice per week.
Weights were taken once per week initially and three times weekly once tumors developed. Tumors were
measured three times weekly by caliper and tumor volume was calculated according to (length x width2)/2.
Treatments were administered twice a week by intraperitoneal injection. All animals were euthanized once the
tumor volume reached 1000 mm 3 or after a maximum of 4 weeks of treatment. In the analysis, mice injected
with adherently and sphere grown U3013MG were pooled and data was analyzed using a linear mixed-effect
model, with data from n=22 mice in total (statistics section, below) (Figure 6E).
Validation of functional associations and synergistic drug combinations
Modulation of proteasome inhibitors by heat, antioxidants and potentiating drugs
To measure whether antioxidants or heat-induced accumulation of ROS could have a protecting or potenti-
ating effect in bortezomib treated GBM cells, we analyzed their viability in drug pair combination assays.
Primary GBM cultures were treated by vehicle, bortezomib (10nM), or combination of bortezomib (10 nM)
with N-acetylcysteine (1 mM, Sigma-Aldrich) or myricetin (200 µM, Selleck Chemicals). The effect of heat
on bortezomib treated GBM cells was assessed by inducing 42 centigrade heat shock during 4 hours concomi-
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tantly with bortezomib (10 nM) addition (Figure S4D). For each cell culture, cells were seeded in separate
plates for control (37°C) and heat treatment (42°C). Primaria 96-well plates (VWR) were coated with laminin
and incubated for 30 min at 37°C, before 5000 cells per well were seeded and incubated overnight at 37°C
before treatment. For each cell culture, bortezomib (22 nM) and corresponding control DMSO were added to
all plates, and the heating plates were incubated at 42°C for 4-, 24- and 48 hours, while their individual control
plates were incubated at 37°C. Viability read was performed using the Wallac Victor 1420 multilabel counter
(Perkin Elmer). To assess potential synergism between bortezomib and other compounds (Figure 7A-E), 10
GBM cultures were seeded in 96 well plates 5.000 cells/well and allowed to attach overnight. The next day,
two proteasome inhibitors, bortezomib (1 µM) and marizomib (1 µM) were added in 6x6 pairwise combinations
with 25 drugs identified in our integrative data analysis (drugs and dose ranges in Table S6). The highest con-
centration of each drug was set to around twofold the IC50 value identified in the literature. Cells in the control
wells were treated with DMSO (0.1 %, corresponding to 10 µM drug; or highest concentration of the drug
dilutions, but not exceeding 0.3 %). After 72h incubation alamarBlue® cell viability reagent (Thermo Fisher
Scientific) was added and fluorescent readout made by Wallac 1420 Victor2 (Perkin Elmer). The resulting
viability data was used to compute Combination Index scores as previously described (Schmidt et al., 2016).
For further validation in a 3D tumor model over an extended time period, combinations of bortezomib with
navitoclax or milciclib were selected for treatment of one bortezomib sensitive and one bortezomib resistant
cell line over 10 days.
Sphere growth combination treatments
For Figure 7F-H, a total of 2000 cells from GBM cultures U3013MG and U3008MG were seeded in PrimeSur-
face 96U S-BIO plates (MoBiTech) in NSC medium with 2.5% matrigel basement membrane matrix (Corning).
Following a short centrifugation step (30 sec at 1000 rpm), cells were incubated for two days to allow sphere
formation before adding treatments consisting of vehicle control, single drugs or combinations of bortezomib
with navitoclax or milciclib diluted in DMSO. An initial dose-response screen with the single drugs and com-
binations in three-fold dilutions spanning a dose range from 100-1 nM (bortezomib), 1-0.11 µM (navitoclax)
and 2-0.22 µM (milciclib) with two replicates per well was performed to select the most efficient combinations
for a second phase experiment with seven replicate per treatment condition. In the second phase, two concen-
trations of bortezomib (3 and 10 nM) were combined with three different concentrations of navitoclax (1 µM,
0.33 µM and 0.11 µM) or milciclib (2 µM, 0.66 µM, 0.22 µM). Images were acquired with the Phase and
Brightfield channels every 6 hours for an additional 10 days on the IncuCyte S3 instrument (Sartorius) using
the spheroid scan module with the 4x objective. Brightfield channel images were segmented using the IncuCyte
2019B Rev2 software and the largest sphere area in each image was measured. Sphere size in cells treated with
drug combinations was compared to the single bortezomib treatments using a one-way ANOVA with Dunnett’s
multiple comparisons test. Single drug treatments were also compared to the combination treatment using
26
Student’s t-tests. Statistical analyses were done in GraphPad Prism version 7.05.
BrdU cell cycle flow cytometric analysis of bortezomib treated GBM cultures
For Figure S5, immunofluorescent staining of incorporated bromodeoxyuridine (BrdU) was performed using
BrdU-FITC specific antibodies according to the manufacturer’s instructions (BD Pharmingen, 559619) coupled
with 7-amino-actinomycin (7-AAD) staining to permit cell cycle position analysis of cells with actively syn-
thesizing DNA. Two proteasome inhibitor sensitive and two proteasome inhibitor-resistant GBM cultures were
treated with DMSO vehicle, 10 or 50 nM bortezomib for 24 hours. During the final 1 hour of cultures, the cells
were pulsed with 10 µM of BrdU before processing according to the BrdU Flow Kit protocol. Cell-associated
BrdU levels and DNA content was measured on a CytoFLEX platform (Beckman Coulter) equipped with a
488-nm laser and analyzed using the CytExpert software version 2.4.
QUANTIFICATION AND STATISTICAL ANALYSIS
Algorithms for glioblastoma subtype assignment
Four methods for subtype assignment were combined by a weighted majority vote to designate one subtype
for each primary GBM culture. Using the Verhaak(Verhaak et al., 2010) gene signature, NTP(Hoshida, 2010),
ssGSEA(Barbie et al., 2009), k-NN(Xie et al., 2015), and nearest centroid were run using 1000 bootstrap runs
resampling cell cultures. A majority vote over the 1000 runs gave the subtype vote for each classifier.
Drug target annotation
We annotated our drug library by Chemical Abstract Service (CAS) identifier, International Chemical Identifier
(InChI) and STITCH database (CIDs/CIDm) identifiers. As a secondary source, we linked our library to the
Drug Repurposing Hub. Target assignments were derived from the Drug Repurposing hub and STITCH. In the
latter case, target assignments are gradual, and we used all targets with a score of at least 700/1000.
Algorithms for drug activity similarity and cluster analysis
From the 1544 compounds in Phase 1, 212 were selected based on their activity. Using drug targets annotated as
described above, a randomization test (randomizing the drug-target annotations 10000 times) was run to derive
an empirical p-value for the frequency of targets selected among the 212 drugs. This resulted in 75 targets with
an empirical p-value of less than 0.05. The most highly enriched targets are shown in Figure 2A. Clustering
of cell cultures and drugs was performed by compiling a matrix of mean viability across doses for each drug
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in each cell culture (cell cultures x compounds). To define subgroups of cell cultures, consensus clustering
(Wilkerson and Hayes, 2010) using hierarchical clustering and Pearson distance metric was implemented using
the ConsensusClusterPlus package in R Bioconductor. When clustering cell cultures, only the 80 compounds in
the intersect between Phase 2 and Phase 3 was used. The optimal number of clusters was selected based on the
diagnostic plots generated in the consensus clustering procedure (Figure S2A). To cluster drugs, a hierarchical
clustering with Pearson distance metric and average linkage was used. The pairwise distances were computed
omitting missing values. The final clusters were obtained using the cutreeDynamicTree function from the
dynamicTreeCut package in R with the option deepSplit set to TRUE (Langfelder et al., 2008) and the minimum
module size set to 5. For the heatmap in Figure 2, missing values were imputed using the impute-knn method in
R, but the imputed values were not used in the clustering. A standard PCA solver (Matlab) was used for PCA
calculations (Figure 4A,B, Figure In cases where more than one data type was used, all data were Z-transformed
and stacked into a single matrix, before PCA.
Algorithms for construction of biomarker-drug network: drug response prediction based on multi-omic
data
Prediction of drug response (quantified as the AUC score for each cell culture and drug) was performed using
Random Forest (RF) (Breiman, 2001) and Elastic-Net (?) methods implemented in R (randomForest, glmnet).
Predictions were run for each drug separately (predicting one drug at a time), and using each datatype (mRNA
expression, CNA, methylation, mutation) individually and in all unique combinations (e.g. CNA-methylation,
methylation-mutation, methylation-mutation-CNA). For methylation data, the set of probes was reduced by
removing probes methylated above an average value of 0.4 in reference brain using data from GEO series
GSE41826 (Guintivano et al., 2013). Methylation was then summarized at the gene level by averaging the
values of methylation probes in CpG islands within 1500 bases of the gene TSS. Gene level mutation data
were filtered to include only genes with at least two mutated cases. Leave-one-out (LOO) cross-validation
was used to access the prediction performance by computing the Pearson correlation between the predicted
and true values. Within each LOO-fold, internal cross-validation was used to select method parameters (e.g.
lambda value for Elastic-Net). For each LOO-fold the variable importance was recorded (variable importance
measure for RF and the absolute value of the Elastic-Net coefficient for Elastic-Net) and averaged over all
LOO-folds for a particular drug. To construct the drug-variable network a variable was linked to a drug if the
drug response was predicted with a Pearson correlation value above 0.2 and if that variable was among the top
50 most important variables for at least one prediction instance. The rather low threshold is used to encourage
common predictors between drugs, and to allow for subsequent filtering of the network. To evaluate the impact
of cross-validation method we compared 10-fold and leave-one-out CV using elastic net and expression data as
the predictor. The 10-fold CV was averaged over 1000 runs. The prediction performance (CV-R) between the
CV showed a Pearson correlation of 0.87. For each drug, a GSEA analysis (Subramanian et al., 2005) using
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the javaGSEA Jar file v 3.0 and MSigDB Hallmark gene sets (Liberzon et al., 2015), was performed using
the gene expression data (filtered to the 10000 genes with highest standard deviation across cell cultures) with
the drug response as a continuous phenotype (1000 permutations of the phenotype with Pearson correlation
metric). A drug is linked to an MSigDB pathway if the FDR q-value is less than 0.25. The links between drugs
and MSigDB pathways were then added to the total network.
Algorithms for scoring drug synergism
The effect on viability of each drug dose was calculated as a viability ratio W = (Ytreated-Yblank)/(Ycontrol-
Yblank), where Ytreated represents the fluorescence signal in treated wells, Ycontrol the signal in vehicle-
treated (DMSO) wells, and Yblank is the technical background measured as the signal in cell-free (medium
only) wells. Since drug pairs were analyzed across 6x6 pairwise combinations, we used a summary statistic
defined as the minimum among the 6x6 epsilon values. Applied to the same data, we used the combination
index, CI, defined as CI(W ) = da(W )/Da(W )+db(W )/Db(W ), where Da(W ) and Db(W ) are the single-
agent dose of drugs a and b needed to reduce viability to level W, and da(W ), db(W ) are the doses of a and
b needed to reduce viability to level W, when used as a combination. For the single dose data in the sphere
experiments (Figure 7G,H), the simpler Bliss method was used, whereby the combination phenotype Wab is




Supplemental Excel File Legends
Table S1: overview of primary glioblastoma cell lines and data generated.
Table S2: annotated list of compounds with related properties. The Excel sheet contains compound infor-
mation for the screening library. It comprises (i) Compound metadata (columns 1-9), including name, CAS
and SMILES identifies; (ii) target and mechanism-of-action information (columns 10-19) as obtained from
the STITCH and Drug Repurposing Hub databases and other sources; (iii) statistics from automated Pubmed
searches (columns 20-24), indicating the number of publications involving each compound (as mentioned in
the abstract or title) overall and co-mentioned with terms like ’glioblastoma’; and, (iv) statistics from the drug
screen, including average AUC score, and CV-R as explained in each heading.
Table S3: summary statistics of predictive power for different drug classes. Drug categories whose re-
sponse can be predicted in primary GBM cells. n is the number of drugs in each category. CV-R is the average
cross-validation correlation per drug category. P values: Student’s t-test.
Table S4: p53 status of each cell line as determined by Sanger sequencing.
Table S5: qPCR primers used for figure S4A.
Table S6: doses used for each drug in the potentiation experiments in Figure 7.
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